Perspective Therapeutics(CATX) - 2026 Q1 - Quarterly Results

Filing Information Details registrant identification, principal offices, and registered securities for Perspective Therapeutics, Inc Registrant Information Provides core identification details for Perspective Therapeutics, Inc., including incorporation, principal executive offices, and registered securities - Registrant: Perspective Therapeutics, Inc., incorporated in Delaware[2] - Principal Executive Offices: 2401 Elliott Avenue, Suite 320, Seattle, Washington 98121, Telephone: (206) 676-0900[2] Registered Securities | Title of each class | Symbol(s) | Name of each exchange on which registered | | :------------------ | :-------- | :---------------------------------------- | | Common Stock, $0.001 par value | CATX | NYSE American LLC | Item 2.02 Results of Operations and Financial Condition Perspective Therapeutics, Inc. announced updated interim clinical trial results and preliminary estimated financial information as of September 30, 2025, noting these figures are unaudited and subject to change - On October 20, 2025, the Company announced updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for neuroendocrine tumors[6] - The Press Release and Presentation include estimated cash, cash equivalents, and short-term investments as of September 30, 2025[6] - All estimated and projected financial information is preliminary, unaudited, and not reviewed by the independent registered public accounting firm[6][7] Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits Details the filing of a Press Release and Presentation as exhibits to the 8-K report, providing further clinical and business updates - On October 20, 2025, the Company issued a Press Release and Presentation, both filed as exhibits to this 8-K report[8] Filed Exhibits | Exhibit No. | Description | | :------------ | :-------------------------------------------------- | | 99.1 | Press Release dated October 20, 2025 | | 99.2 | Presentation | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | Signatures The report was officially signed on October 20, 2025, by Johan (Thijs) Spoor, CEO of Perspective Therapeutics, Inc., affirming compliance - The report was signed by Johan (Thijs) Spoor, Chief Executive Officer of Perspective Therapeutics, Inc., on October 20, 2025[14]